ソース:[1] WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial (https://finance.yahoo.com/news/winrevair-sota ...)[2] Merck & Co.'s Winrevair cuts progression by 76% in newly diagnosed PAH - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial - Merck.com (https://vertexaisearch.cloud.google.com/groun ...)